newsfilter
← Latest News
ACCESS Newswire·

Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain

~ Engineered to Deliver Potent Pain Relief with Built-In Abuse Protection ~SAN DIEGO, CA / ACCESS Newswire / January 28, 2026 / Ensysce Biosciences, Inc. , a clinical-stage